This collaboration provides clinical validation and cost savings but does not alter Erasca's near-term cash burn or regulatory path. Monitor AURORAS-1 enrollment and early efficacy data for read-through on ERAS-0015's potential. The stock may see a modest positive reaction on partnership credibility, but no fundamental change.
Price Chart
Executive Summary
Erasca announced a clinical trial collaboration with Merck to evaluate its pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA for RAS-mutant solid tumors. Merck will supply pembrolizumab at no cost, and Erasca will sponsor the AURORAS-1 study. This is a non-financial collaboration that provides validation for Erasca's pipeline but does not change the company's fundamental outlook.
Key Facts
- Erasca entered a clinical trial collaboration and supply agreement with Merck for ERAS-0015 + KEYTRUDA in RAS-mutant solid tumors.
- Merck is supplying pembrolizumab at no cost; Erasca sponsors the AURORAS-1 study.
- ERAS-0015 is an oral pan-RAS molecular glue with early Phase 1 data showing favorable safety and partial responses at doses as low as 8 mg QD.
- Approximately 2.7 million patients are diagnosed annually with RAS-mutant tumors worldwide.
- No financial terms of the agreement were disclosed.
Financial Impact
No financial terms disclosed; Merck's supply of pembrolizumab at no cost reduces Erasca's trial expenses modestly.
Risk Factors
- ERAS-0015 is still in early Phase 1; clinical failure remains a significant risk.
- Revolution Medicines has alleged patent infringement regarding ERAS-0015, which could lead to litigation delays.
- Combination trial may not show additive benefit over monotherapy or existing standards.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291730 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | 8-K | $17.60 $15.55 | ▼ −11.65% | ▼ −12.96% | $14.94 (−15.09%) |
Aug 17, 2026 6w ago | 144 | $18.28 $16.16 | ▼ −11.60% | ▼ −10.07% | $14.94 (−18.24%) |
Aug 13, 2026 7w ago | Institutional Cluster | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 12, 2026 7w ago | 3 | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 11, 2026 7w ago | Press Release | $18.58 $16.03 | ▼ −13.72% | ▼ −11.83% | $14.94 (−19.56%) |
Jul 22, 2026 10w ago | Press Release | $19.51 $18.07 | ▲ +7.38% | ▲ +10.28% | $14.94 (+23.40%) |
Jul 14, 2026 11w ago | 8-K | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | 424B5 | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | Press Release | $19.50 $18.31 | ▲ +6.10% | ▲ +8.59% | $14.94 (+23.36%) |
Jul 13, 2026 11w ago | Press Release | $19.50 $18.31 | ▼ −6.10% | ▼ −8.59% | $14.94 (−23.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access